OFG
NAVB

OTA Financial Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

OTA Financial Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-65,600
Closed -$258K – 86
2020
Q2 		$258K Buy
+65,600
New +$125K 0.29% 35

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OTA Financial Group's NAVB Position: Q3 2020 in Review

OTA Financial Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2020, closing a stake of 65,600 shares — an estimated $258K sold.

OTA Financial Group first reported a position in NAVB in Q2 2020 and held it in 1 quarter. The position peaked at $258K in Q2 2020. 38 funds tracked by Wall St. Rank hold NAVB as of Q3 2020.

  • OTA Financial Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2020 after selling out during the quarter.
  • OTA Financial Group sold 65,600 Navidea Biopharmaceuticals Inc. shares in Q3 2020, an estimated $258K.
  • OTA Financial Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2020 and held it in 1 quarter.
  • OTA Financial Group's Navidea Biopharmaceuticals Inc. position peaked at $258K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2020.

Based on OTA Financial Group's 13F filing for Q3 2020, filed 28 Oct 2020.